// App-Quantinova.ai

122 : Preclinical and Clinical Assessments of the Abuse Potential of the Kappa-Opioid Receptor Agonist CR845 Suggest Low Abuse Potential

Researchers

Presenter

  • Frdrique Menzaghi

Principal Investigators

  • David Heal

  • Catherine Munera

  • Joseph W. Stauffer

  • Robert Spencer

Medical Centers

  • Cara Therapeutics, Inc., Stamford, CT, USA

  • RenaSci Ltd, BioCity, Nottingham, UK

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Lactate

Drug/Treatment

  • Butorphanol

  • Pentazocine

  • Epimorph

  • Difelikefalin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Cross Over

  • Double Blind/Blinded

  • Controlled

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved